Update of interferon use in acute simple bronchitis in children


  • A.E. Abaturov State Institution “Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine”, Dnipro, Ukraine http://orcid.org/0000-0001-6291-5386
  • N.M. Tokarieva State Institution “Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine”, Dnipro, Ukraine




acute simple bronchitis, children, immunity, interferon alpha 2b, interferon gamma, lactoferrin, α-defensins


Background. The main etiological factors of acute simple bronchitis in children are respiratory viruses, and therefore interferon preparations can be used in the treatment of these respiratory diseases. The purpose of the work was to study the clinical and immunological efficacy of recombinant alpha 2b interferon in the treatment of acute simple bronchitis in children. Materials and methods. We have examined 49 children aged 2 to 6 years with acute simple bronchitis; 23 children received Laferobion® containing recombinant alpha 2b interferon. Du­ring the work, clinical and laboratory methods of investigation were used. The severity of the patient’s condition was assessed according to the Bronchitis severity score. The laboratory study included: general blood and urine test, nasocytological, immunoassay methods. The etiological diagnosis was established ­using virological methods of investigation. When determining the concentration of interferon gamma, “Gamma interferon-IFA-BEST A-8752” set manufactured by Vector Best was used; lactoferrin — Нuman Lactoferrin NK 329 Edition 06-16 set manufactured by Hycult Biotech (USA), neutrophil a-defensins 1-3 — Нuman HNP NK317 Edition 08-16 reagents manufactured by Hycult Biotech (USA). Results. In all children with acute simple bronchitis, the disease began acutely and manifested itself with catarrhal and general inflammatory syndromes. According to the evaluation of acute simple bronchitis signs at the onset of the disease and in the period of convalescence ­using Bronchitis severity score, the administration of recombinant alpha 2b interferon promotes a faster reduction of all clinical manifestations of the disease and an increase in the lactoferrin content in the oropharyngeal fluid until the period of convalescence. Conclusions. The rectal administration of recombinant alpha 2b interferon Laferobion® is an etiopathogenetic method for the treatment of acute simple bronchitis in children


Download data is not yet available.


Abaturov AE, Volosovets AP, Yulish EI. Induktsiia molekuliarnykh mekhanizmov nespetsificheskoi zashchity respiratornogo trakta (monografiia) [Induction of molecular mechanisms of non-specific protection of the respiratory tract (monograph)]. Kyiv: Private printing house Storozhuk OV; 2012. 240 p. (in Russian).

Bulgakova VA. Respiratory infections in children: diagnosis, treatment and prevention. Praktika pediatra. 2012;(6):16-28. (in Russian).

Gorelov AV, Feklisova LV, Gracheva NM, Alpenidze DN. Exogenous interferonization as an aspect of etiopathogenetic treatment of acute respiratory viral infections. Pharmateca. 2011;(15):73-81. (in Russian).

Dzhumagaziev AA. Use of imunomodulyators and metabolites for the prophylaxis of acute bronchitis and acute pneumonia in children. Novaia nauka: teoreticheskii i prakticheskii vzgliad. 2016;(117-3):44-45. (in Russian).

Zaytsev AA. Ostrye respiratornye virusnye infektsii: aktual'nye voprosy diagnostiki, lecheniia i profilaktiki [Acute respiratory viral infections: pressing questions of diagnostics, treatments and preventions]. Moscow; 2017. 240 p.

Kryuchko TO, Abaturov OE, Tkachenko OY, Tokarieva NM. Priority of using herbal medicines in the treatment of viral respiratory infections in children. Zdorov`e rebenka. 2018;13(1):28-34. doi: 10.22141/2224-0551.13.1.2018.127062. (in Russian).

Lyisenko IM, Barkun GK, Zhuravleva LN, Matsiushchanka OV, Potapova VE. Etiopatogenetic aspects of therapy of diseases of respiratory diseases in children and adolescents. Okhrana materinstva i detstva. 2016;(28):35-57. (in Russian).

Simovanyan EN, Harabadzhahyan EA, Denisenko VB. Recombinant interferon α2b (Viferon) - efficacy in treatment of acute pediatric obstructive bronchitis. Pediatria. 2008;87(1):19. (in Russian).

Suhorukova DN, Kuznetsova TA. Epidemiology of acute bronchitis and bronchiolitis at children. Evrazijskij souz ucenyh. 2016;(32):19-21. (in Russian).

Chernyshova OYe. Use of Recombinant α-2b-Interferon in the Treatment of Acute Respiratory Viral Diseases in Children. Zdorov`e rebenka. 2016;(74):69-73. doi: 10.22141/2224-0551.6.74.2016.82135. (in Russian).

Yulish EI. Antiviral therapy in the treatment of acute respiratory diseases in children. Sovremennaya pediatriya. 2013;(53):75. (in Russian).

Abboud G, Tahiliani V, Desai P, et al. Natural Killer Cells and Innate Interferon Gamma Participate in the Host Defense against Respiratory Vaccinia Virus Infection. J Virol. 2015 Oct 14;90(1):129-41. doi: 10.1128/JVI.01894-15.

Berlutti FF, Pantanella F, Natalizi T, et al. Antiviral properties of lactoferrin--a natural immunity molecule. Molecules. 2011 Aug 16;16(8):6992-7018. doi: 10.3390/molecules16086992.

Drajac C, Laubreton D, Riffault S, Descamps D. Pulmonary Susceptibility of Neonates to Respiratory Syncytial Virus Infection: A Problem of Innate Immunity? J Immunol Res. 2017;2017:8734504. doi: 10.1155/2017/8734504.

Gualdi L, Mertz S, Gomez AM, Ramilo O, Wittke A, Mejias A. Lack of effect of bovine lactoferrin in respiratory syncytial virus replication and clinical disease severity in the mouse model. Antiviral Res. 2013 Aug;99(2):188-95. doi: 10.1016/j.antiviral.2013.05.013.

Mayeur S. Spahis S, Pouliot Y, Levy E. Lactoferrin, a Pleiotropic Protein in Health. Antioxid Redox Signal. 2016 May 10;24(14):813-36. doi: 10.1089/ars.2015.6458.

Moawad EM, Haron MA, Maher RM, et al. Cross-sectional evaluation of the Bronchitis Severity Score in Egyptian children: A move to reduce antibiotics. S Afr Med J. 2017 Mar 29;107(4):342-345. doi: 10.7196/SAMJ.2017.v107i4.11428.

Molloy CT, Andonian JS, Seltzer HM, Procario MC, Watson ME Jr, Weinberg JB. Contributions of CD8 T cells to the pathogenesis of mouse adenovirus type 1 respiratory infection. Virology. 2017 Jul;507:64-74. doi: 10.1016/j.virol.2017.04.005.

Schmidt ME, Varga SM. Cytokines and CD8 T cell immunity during respiratory syncytial virus infection. Cytokine. 2018 Jul 18. pii: S1043-4666(18)30297-7. doi: 10.1016/j.cyto.2018.07.012.

Siqueiros-Cendón T, Arévalo-Gallegos S, Iglesias-Figueroa BF, García-Montoya IA, Salazar-Martínez J, Rascón-Cruz Q. Immunomodulatory effects of lactoferrin. Acta Pharmacol Sin. 2014 May;35(5):557-66. doi: 10.1038/aps.2013.200.

Velusamy SK, Poojary R, Ardeshna R, Alabdulmohsen W, Fine DH, Velliyagounder K. Protective effects of human lactoferrin during Aggregatibacter actinomycetemcomitans-induced bacteremia in lactoferrin-deficient mice. Antimicrob Agents Chemother. 2014;58(1):397-404. doi: 10.1128/AAC.00020-13.

Wakabayashi H, Oda H, Yamauchi K, Abe F. Lactoferrin for prevention of common viral infections. J Infect Chemother. 2014 Nov;20(11):666-71. doi: 10.1016/j.jiac.2014.08.003.

Ward PP, Mendoza-Meneses M, Park PW, Conneely OM. Stimulus-dependent impairment of the neutrophil oxidative burst response in lactoferrin-deficient mice. Am J Pathol. 2008 Apr;172(4):1019-29. doi: 10.2353/ajpath.2008.061145.

Zhao M, Chen J, Tan S, et al. Prolonged evolution of virus-specific memory T cell immunity post severe avian influenza A (H7N9) virus infection. J Virol. 2018 Jun 20. pii: JVI.01024-18. doi: 10.1128/JVI.01024-18.



How to Cite

Abaturov, A., & Tokarieva, N. (2021). Update of interferon use in acute simple bronchitis in children. CHILD`S HEALTH, 13(7), 635–641. https://doi.org/10.22141/2224-0551.13.7.2018.148916



Clinical Pediatrics

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 > >>